StockData
Viking Therapeutics, Inc. logo

Viking Therapeutics, Inc. (VKTX) company profile

VKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 5/30
$26.88+0.08 (+0.30%)

Close on Nov 17, 2026Market cap $3.43BP/E –Yield –

About Viking Therapeutics

Pharmaceutical Preparations, SIC 2834

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing therapies for metabolic and endocrine disorders. Its product pipeline includes VK2735, a dual GLP-1 and GIP receptor agonist being evaluated in subcutaneous and oral formulations for obesity and metabolic conditions. The company is also developing VK2809, an orally available thyroid hormone receptor beta agonist targeting non-alcoholic steatohepatitis, and VK0214, an orally available thyroid hormone receptor beta agonist for X-linked adrenoleukodystrophy. Additionally, its pipeline includes VK5211, a selective androgen receptor modulator studied for recovery following hip fracture surgery, as well as an internally developed dual amylin and calcitonin receptor agonist program.

The company operates in the United States and conducts its research and clinical programs through multi-center trials across various study cohorts. Viking Therapeutics maintains its principal executive offices in San Diego, California.

Summary of the business section of Viking Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Viking Therapeutics, Inc.
Founded
2012
Headquarters
San Diego, CA
Address
9920 Pacific Heights Blvd, Suite 500
Phone
(858) 704-4660
Employees
53, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Marcum llp, Costa Mesa, California

Stock & identifiers

Ticker
VKTX
Exchange
Nasdaq
IPO date
Apr 29, 2015
Shares outstanding
128M, Oct 15, 2026
Public float
$2.98B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1607678
CUSIP
92686J106
ISIN
US92686J1060
FIGI
BBG006LGV869
Share class FIGI
BBG006LGV887
LEI
529900IVC72YPFA25M37
EIN
46-1073877

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Brian LianPresident & CEO, Director2,572,441
Greg ZanteChief Financial Officer212,204
Marianna ManciniChief Operating Officer422,760
Hubert C. ChenChief Medical Officer–
Neil William AubuchonChief Commercial Officer4,475
Dorothy Elizabeth Kelly-GemmellDirector6,333
Lawson MacartneyDirector51,115
Matthew W. FoehrDirector132,036
Sarah Kathryn RouanDirector4,390
Charles A. Rowland JrDirector33,150
J. Matthew SingletonDirector12,650

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$21.27M$7.50M$5.15M$625$125
FY2024$14.30M$106.75M$4.69M$715$93
FY2023$12.63M$36.95M$3.50M$331$94
FY2022$5.41M$13.26M$1.88M$167$90
FY2021$4.06M$2.81M$1.43M$82$100

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payTotalvs. prior year
Brian Lian, Ph.D.
Chief Executive Officer
$672.00K$17.76M$2.47M$373.00K$21.27M+49%
Marianne Mancini
Chief Operating Officer
$540.00K$3.23M$1.17M$225.00K$5.16M+10%
Greg Zante
Chief Financial Officer
$521.00K$3.23M$1.17M$217.00K$5.14M+10%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Apr 29, 2015
Offer price
$8.00
Securities offered
3,000,000
Gross proceeds
$24.00M
Exchange
Nasdaq
First trading day
Apr 28, 2015
First-day close
$8.000.0%
Lock-up ends (est.)
Oct 25, 2015

“Per Share Total Price to the public $ 8.00 $ 24,000,000 Underwriting discount(1) 0.64 1,760,000 Proceeds to us, before expenses 7.36 22,240,000 (1) Does not include a non-accountable expense allowance equal to 0.375% of the gross proceeds of this offering (excluding the gross proceeds from any shares purchased by L”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had fifty-three full-time employees, twelve of whom hold a Ph.D.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?